Roger Ulrich

Dr. Roger Ulrich has thirty years of experience in pharmaceutical R&D in both large and small company settings. He was Founder and Chief Development Officer at Calistoga Pharmaceuticals Inc., where he led the development of idelalisib for the treatment of patients with hematologic malignancies; Calistoga Pharmaceuticals was acquired in 2011 by Gilead Sciences. Prior to Calistoga, Dr. Ulrich was Senior Scientific Director with Merck Research Laboratories-Rosetta Inpharmatics, Director Regulatory Toxicology & Safety Pharmacology, and Cellular and Molecular Toxicology with Abbott La​boratories, and as Senior Scientist with The Upjohn Company and Pharmacia & Upjohn Inc. Dr. Ulrich holds several patents and has authored more than 120 publications.

Dr. Ulrich received a Bachelor of Arts degree in Biology/Chemistry and a Masters of Arts in Biomedical Sciences from Western Michigan University. He received his doctorate in Cellular and Molecular Biology from West Virginia University, and is a Fellow of the Academy of Toxicological Sciences.